Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Penumbra ( (PEN) ) has provided an update.
On January 14, 2026, Penumbra, Inc. entered into a definitive merger agreement under which Boston Scientific will acquire Penumbra through a merger of a Boston Scientific subsidiary into Penumbra, leaving Penumbra as a wholly owned subsidiary of Boston Scientific. At closing, each Penumbra common share will be converted into either 3.8721 Boston Scientific shares or $374 in cash, subject to shareholder elections and proration so that roughly 73% of Penumbra shares receive cash and 27% receive stock, with detailed treatment laid out for stock options and restricted stock units. The transaction, which is not subject to a financing condition, remains contingent on approval by Penumbra shareholders, antitrust and other regulatory clearances, effectiveness of Boston Scientific’s registration statement and NYSE listing approval for the new Boston Scientific shares; once completed, Penumbra’s securities will be delisted from the NYSE, and the agreement includes substantial reverse and standard termination fees tied mainly to competing bids, board recommendation changes and failure to obtain antitrust approvals. Separately, on January 15, 2026, Penumbra reported unaudited preliminary results indicating strong operational momentum for 2025, with fourth-quarter revenue of $383.0 million to $384.8 million, up about 21% to 22% year on year (over 23% excluding China), and full-year revenue of $1.401 billion to $1.403 billion, up about 17% to 18% (nearly 25% excluding China), supported by gross margins around 68% in the fourth quarter and 67% for the year and operating margins rising into the mid-teens, highlighting robust growth and profitability as the company moves toward integration with Boston Scientific.
The most recent analyst rating on (PEN) stock is a Buy with a $355.00 price target. To see the full list of analyst forecasts on Penumbra stock, see the PEN Stock Forecast page.
Spark’s Take on PEN Stock
According to Spark, TipRanks’ AI Analyst, PEN is a Outperform.
Penumbra’s strong financial performance and positive earnings call are the most significant factors driving the score. The company’s robust revenue growth and improved profitability are key strengths. However, the high P/E ratio suggests potential overvaluation, and technical indicators show an overbought condition, which could pose risks.
To see Spark’s full report on PEN stock, click here.
More about Penumbra
Penumbra, Inc., listed on the NYSE under the ticker PEN, is the world’s leading thrombectomy company, focused on developing innovative technologies to treat challenging vascular conditions including ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Its broad portfolio, notably computer assisted vacuum thrombectomy (CAVT), is designed to remove blood clots throughout the body and is used by healthcare providers, hospitals and clinics in more than 100 countries to improve patient outcomes and quality of life.
Average Trading Volume: 504,708
Technical Sentiment Signal: Buy
Current Market Cap: $12.27B
See more insights into PEN stock on TipRanks’ Stock Analysis page.